You are here: Industry Insights > Financial Report

News List

Financial Report； Lilly contractpharma
October 29, 2020
Comments: Key growth products launched since 2014, consisting of Taltz, Trulicity, Verzenio, Jardiance, Olumiant, Emgality, Tyvyt, Baqsimi, Cyramza, Retevmo and Basaglar contributed nearly 9 percentage points of revenue growth and represented ...
Financial Report: Biogen contractpharma
October 28, 2020
Commetns: Multiple sclerosis revenues, including $272 million in royalties on sales of OCREVUS, decreased 4%. Total Interferon sales (AVONEX and PLEGRIDY) were down 11% to $474 million.
Financial Report; Johnson & Johnson contractpharma
October 19, 2020
Pharmaceutical sales were up 5% in the quarter to $11.4 billion.
Financial Report, Pfizer contractpharma
August 13, 2020
Biopharma revenues were $9.8 billion, up 6% operationally, primarily driven by Vyndaqel.
Financial Report, Lilly contractpharma
August 12, 2020
Trulicity revenues up 20% in the quarter, driven by increased demand.
Financial Report: Abbvie contractpharma
August 12, 2020
Revenues in the quarter up 26% boosted by Immunology portfolio and Allergan aesthetics portfolio.
Financial Report: Akorn contractpharma
August 12, 2020
Revenues down 32% in the second quarter.
Financial Report - Amgen contractpharma
May 04, 2020
Newer products, including Otezla, Repatha, MVASI, KANJINTI and Evenity, partially offset declines due to biosimilar competition.
Financial Report - Abbvie contractpharma
May 04, 2020
Global HUMIRA revenues were $4.7 billion, up 6% in the quarter.
Financial Report -Pfizer contractpharma
April 30, 2020
Biopharma revenues up 11% in the quarter to $10.0 billion; generic competition impacts Upjohn revenues.

Previous page 1 2 3 Next page